Skip to content
Screener

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$116.09B+1.0%
Amgen logo
AmgenAMGN
$937M-15.5%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
$146.35M+48.3%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$136.19M-14.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$44M-12.0%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemMarch 31, 2026December 31, 2025
Related party accounts payable and other current liabilities3,0049
Total current liabilities16,63315,374
Operating lease liability, non-current1,1271,313
Total liabilities17,76016,687
Commitments and contingencies (Note 11)
Stockholders’ equity:
Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of March 31, 2026 and December 31, 2025; 137,138 shares issued and outstanding as of March 31, 2026 and December 31, 20252,9312,931
Common stock, $0.001 par value; 545,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 50,167,623 and 48,722,309 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively5049

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s total liabilities?
Oruka Therapeutics, Inc. (ORKA) reported total liabilities of $17.76M in Q1 2026.
How has Oruka Therapeutics, Inc.'s total liabilities changed year-over-year?
Oruka Therapeutics, Inc.'s total liabilities increased by 43.4% year-over-year, from $12.39M to $17.76M.
What is the long-term trend for Oruka Therapeutics, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s total liabilities has grown at a 33.7% compound annual growth rate (CAGR), from $3.91M to $16.69M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Oruka Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude